# How a 2026 blood assay separated two growth hormone fragments

- Article ID: research-116
- Product: Fragment 176-191 (fragment-176-191-435)
- Canonical page: https://heritagebiolabs.com/research-library/articles/116-how-a-2026-blood-assay-separated-two-growth-hormone-fragments
- Product collection: https://heritagebiolabs.com/research-library/products/fragment-176-191
- Product page: https://heritagebiolabs.com/product/fragment-176-191-435
- Reading focus: Methods & identity (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 1986, 2024, 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short chains of amino acids joined by peptide bonds. Their sequences determine properties such as mass and can help laboratories distinguish closely related molecules. Human growth hormone Fragment 176–191 is the last 16 amino acids of the mature hormone. A 2026 analytical study included both this fragment and the related, modified peptide AOD-9604. The investigators asked whether a single laboratory workflow could detect both among many other compounds in blood samples. [1, 2, 3]

The team used liquid chromatography to separate components of the samples and high-resolution mass spectrometry to distinguish them by their mass-related signals. The method covered 54 peptide and nonpeptide compounds. It was evaluated in serum, plasma and dried blood spots. The study also asked whether samples would still contain detectable target material after storage, since a result can depend on what happens between sample collection and measurement. [1]

Both hGH 176–191 and AOD-9604 were among the peptides that degraded substantially in serum and plasma after a week at the study’s warmer conditions. Across the study, the compounds remained detectable in the dried samples for the tested intervals. The comparison belongs to the experimental blood matrices and storage conditions. It demonstrates how the sample can affect measurement, and it does not describe how long the fragment remains active inside a person. [1]

Listing the two fragments separately matters. The native sequence begins with phenylalanine, while AOD-9604 starts with tyrosine and shares the following 15 residues. A laboratory method that treats them as distinct targets can reduce the risk of assigning a signal from one to the other. This recent study gives direct evidence about detection and sample stability. It did not test what either peptide does to body weight or glucose in people. [1, 2, 3]

## Sources

1. Monica Mazzarino et al. Rapid and harmonized analytical workflow for the determination of peptidic and non-peptidic doping agents in dried and liquid blood matrices. The Analyst (publication 2026-07-27). <https://pubmed.ncbi.nlm.nih.gov/42328738/>
2. UniProt Consortium. GH1 - Somatotropin - Homo sapiens (Human). UniProtKB P01241 (publication 1986-07-21, record updated 2026-11-04). <https://www.uniprot.org/uniprotkb/P01241/entry>
3. U.S. Food and Drug Administration. FDA Evaluation of AOD-9604-Related Bulk Drug Substances (AOD-9604 (free base) and AOD-9604 acetate). Pharmacy Compounding Advisory Committee briefing (publication 2024-12-04). <https://www.fda.gov/media/183584/download>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 024 - Fragment 176-191.docx; article 116; content SHA-256 ccb8df6eb848aadda93146ef4c7b9f7c75bd3311bf37381290671f6633409f87.
